

"Express Mail" Label No. EV 330853779US
Date of Deposit: September 22, 2003

PATENT
Attorney Docket No.: 021167-000750US

This is being deposited with the United States Postal Service "Express Mail
Post Office to Address" service under 37 CFR 1.10 on the date indicated
above and is addressed to:

MAIL STOP PATENT APPLICATION
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Robert F. Balint, *et al.*

Continuation of Application
No.: 09/526,106

Filed: March 15, 2000

For: BREAKPOINT FUSION
FRAGMENT COMPLEMENTATION
SYSTEM

Examiner: Epperson, Jon D.

Art Unit: 1639

COMMUNICATION UNDER

37 C.F.R. §§ 1.821-1.825

AND

PRELIMINARY AMENDMENT

Mail Stop Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicants respectfully request entry of the following amendments to the claims and specification. In addition, Applicants submit the following sequences in compliance with the Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821-1.825. Applicants submit that the computer-readable form in the instant application is identical with that filed in Application No. 09/526,106, filed February 26, 2003. In accordance with 37 C.F.R. § 1.821(e), please use the computer-readable form filed in Application No. 09/526,106 as the computer-readable form for the instant application. A paper copy of the Sequence Listing from Application No. 09/526,106 is

submitted herewith. The information in the paper copy of the Sequence Listing is identical to that which is in the computer readable form, as required under 37 C.F.R. § 1.821(f).

It is understood that the Patent and Trademark Office will make the necessary changes in application number and filing date for the computer-readable form that will be used for the instant application.

Please amend the specification in adherence with 37 C.F.R. §§ 1.821-1.825 as follows.

Amendments to the Claims begin on page 3 of this paper.

Amendments to the Specification begin on page 6 of this paper.

Remarks begin on page 19 of this paper.